Transforming growth factor-beta-1 gene therapy

Drug Profile

Transforming growth factor-beta-1 gene therapy

Latest Information Update: 26 Aug 2002

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Gene therapies; Growth factors
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Rheumatoid arthritis; Transplant rejection

Most Recent Events

  • 31 Jul 1998 Preclinical development for Rheumatoid arthritis in USA (IM)
  • 02 Jun 1995 Preclinical development for Transplant rejection in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top